NEW YORK (GenomeWeb) – Merck and NanoString Technologies today announced a research collaboration to develop an assay to evaluate the potential benefits to a patient treated with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).

The assay will be based on immune-related gene expression signatures and will be developed using NanoString's nCounter analysis system to optimize gene expression signatures as part of the clinical development of Keytruda.

Keytruda is a monoclonal antibody that blocks interaction between PD-1 and its ligands.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.